CRDL

Cardiol Therapeutics Inc. CRDL

NasdaqSmall CapHealthcare

13F Pro Quality Score

Not in ranked universe

Below size threshold

Below the main board's size threshold of $25M annual revenue or $100M total assets. This company reported $0.1M in revenue and is scored on the micro-cap board instead.

Financial data, filings, and institutional holdings below are still tracked in full — only the proprietary quality composite is unavailable for this name.

Net income

$-36.68M

Quarter to Dec 31

Free cash flow

$-25.08M

Quarter to Dec 31

Top Institutional Holders

as of Q2 2026
$31.29M total
MMCAP International Inc. SPC
$16.53M+1.6%
Tejara Capital Ltd
$5.42M-0.3%
Ikarian Capital, LLC
$3.52M+22.0%
BOOTHBAY FUND MANAGEMENT, LLC
$1.03M+22.8%
CITADEL ADVISORS LLC
$844.3K-2.9%
RENAISSANCE TECHNOLOGIES LLC
$819.2K+236.3%
TWO SIGMA INVESTMENTS, LP
$791.8K+39.8%
INTEGRITY ALLIANCE, LLC.
$411.8K-16.5%
MORGAN STANLEY
$376.3K+41.8%
GOLDMAN SACHS GROUP INC
$353.9K+0.5%
PVG ASSET MANAGEMENT CORP
$113.6K0.0%
MGO ONE SEVEN LLC
$106.0K0.0%
1832 Asset Management L.P.
$106.0K0.0%
Summit Financial, LLC
$105.1K-4.8%
JANE STREET GROUP, LLC
$56.1K-57.9%
HRT FINANCIAL LP
$50.0KNew
JPMORGAN CHASE & CO
$49.5K0.0%
ACADIAN ASSET MANAGEMENT LLC
$45.0KNew
GEODE CAPITAL MANAGEMENT, LLC
$44.7K-19.5%
Marble Harbor Investment Counsel, LLC
$42.3K0.0%
Boyer Financial Services, Inc.
$35.8K+47.6%
SECURITY NATIONAL BANK OF SIOUX CITY IOWA /IA/
$35.0K0.0%
Quadrature Capital Ltd
$32.4K-36.2%
Kovack Advisors, Inc.
$31.5K0.0%
Concurrent Investment Advisors, LLC
$26.9KNew
See all 53 institutional holders →
Reading the latest SEC filing…

Key Metrics

Net Income

FY 2024
EDGAR

EPS (Diluted)

FY 2024
EDGAR

Free Cash Flow

FY 2024
EDGAR

Loading ratio trend…

CRDL key financials by period

Reported revenue, net income and operating margin by fiscal year, from Cardiol Therapeutics Inc.'s annual filings on SEC EDGAR.

Cardiol Therapeutics Inc. reported revenue, net income and margins by fiscal period, from SEC filings.
PeriodRevenueNet incomeOp. margin
FY 2021$78.8K$-31.6M—
Source: CRDL filings on SEC EDGAR →

About Cardiol Therapeutics Inc. (CRDL): stock profile, AI score and financials

Cardiol Therapeutics Inc. (CRDL) stock profile, AI quality score, and SEC EDGAR financial data, a Healthcare sector company. CRDL is not currently included in 13F Pro's AI-ranked quality universe — below the main board's size threshold of $25m annual revenue or $100m total assets. this company reported $0.1m in revenue and is scored on the micro-cap board instead. Based on the latest XBRL financial filings (FY 2024), Cardiol Therapeutics Inc. reports net income of $-36.7M, free cash flow of $-25.1M. Top institutional holders of CRDL by reported 13-F value include MMCAP International SPC, Tejara Capital Ltd, Ikarian Capital, based on the most recent SEC filings. CRDL trades on the Nasdaq exchange and files with the SEC under CIK 1702123. 13F Pro's AI research platform runs 10 specialized AI analysts — value, growth, momentum, macro, and activist specialists — that debate CRDL daily and publish AI-generated analysis with cited SEC sources. The platform aggregates historical XBRL financial facts, 10-Q and 10-K filings, insider Form 4 transactions, and institutional 13-F holdings for Cardiol Therapeutics Inc. directly from SEC EDGAR.

SEC EDGAR: CIK 1702123 →